当前位置:药药网 / 药品研发 / 美国药品上市后承诺数据库
TRUMENBA, Meningococcal Group B Vaccine
申请企业
Wyeth Pharmaceuticals LLC
药品名称
TRUMENBA, Meningococcal Group B Vaccine
承诺描述
A deferred pediatric study (B1971017) under PREA to evaluate the safety and immunogenicity of Trumenba in children 2 years to less than 10 years of age for the prevention of invasive group B meningococcal disease.
承诺状态描述
The final report was submitted to FDA on 11 Oct 2017.
报告接收日期
2020/12/18 0:00:00